May 23, 2023 / 08:00PM GMT
Operator
Good day, and welcome to the Verona Pharma ATS 2023 data call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to David Zaccardelli, Chief Executive Officer. Please go ahead.
David S. Zaccardelli - Verona Pharma plc - President, CEO & Executive Director
Good afternoon, everyone. Thank you for joining the call. With me today are Dr. Tara Rheault, our Head of Research and Development; Dr. Kathy Rickard, our Chief Medical Officer; Chris Martin, Head of Commercial; and Mark Hahn, our Chief Financial Officer. Before we begin, let me remind you that we may be making forward-looking statements, and as such, refer you to our risk section in our recent SEC filings.
It has been a very exciting and productive past few days at the ATS meeting in Washington, D.C. Ensifentrine has been on full display with a comprehensive review of the Phase III ENHANCE trial results. This has included a symposium presentation and 12 abstracts, including subset analyses and pooled analyses from ENHANCE-1 and ENHANCE-2
Verona Pharma PLC To Discuss The Phase 3 ENHANCE Data Presented At ATS 2023 Transcript
May 24, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers